Trials / Withdrawn
WithdrawnNCT00535314
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.
Detailed description
This is a phase II, open label, randomized study in patients with unresectable Stage III or Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA 402 administered orally once daily for 28 consecutive days, for up to 18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RTA 402 Dose1 | |
| DRUG | RTA 402 Dose2 |
Timeline
- First posted
- 2007-09-26
- Last updated
- 2025-05-31
Source: ClinicalTrials.gov record NCT00535314. Inclusion in this directory is not an endorsement.